Department of Hematology and Oncology (Key Discipline of Jiangsu Medicine), Medical School, Zhongda Hospital, Southeast University, No. 87 Dingjiaqiao, Gulou District, Jiangsu Province, 210009, Nanjing, People's Republic of China.
Department of Interventional Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Invest New Drugs. 2021 Oct;39(5):1383-1388. doi: 10.1007/s10637-021-01101-w. Epub 2021 Mar 22.
Background To investigate the clinical efficiency of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) for advanced hepatocellular carcinoma (HCC). Methods This retrospective study enrolled 177 HCC patients, and they were divided into TACE monotherapy group (n = 129) and TACE + RFA group (n = 48) between January 2015 and October 2017. The objective response rate (ORR), disease control rate (DCR), and the survival outcomes were compared between the TACE monotherapy and the treatment of TACE + RFA after propensity score matching (PSM). Results After PSM matching, the confounding factors had no significant differences between the 48 pairs of patients. The DCR was calculated as 33 (69 %) and 42 (88 %) for the TACE monotherapy group and TACE + RFA group, respectively (P < 0.05). And the ORR was calculated as 23 (48 %) and 35 (73 %), respectively (P < 0.05). Moreover, the PFS rate of the TACE + RFA group was significantly higher than the TACE alone group (P < 0.001). Conclusions The treatment of TACE combined with RFA has better tumor response rate and survival rate than the TACE monotherapy for patients with advanced HCC.
研究经导管动脉化疗栓塞（TACE）联合射频消融（RFA）治疗晚期肝细胞癌（HCC）的临床疗效。
本回顾性研究纳入了 177 例 HCC 患者，根据治疗方法的不同将其分为 TACE 单药治疗组（n=129）和 TACE+RFA 治疗组（n=48），两组患者分别在 2015 年 1 月至 2017 年 10 月接受治疗。采用倾向性评分匹配（PSM）后比较 TACE 单药治疗与 TACE+RFA 治疗后的客观缓解率（ORR）、疾病控制率（DCR）和生存结局。
PSM 匹配后，两组 48 对患者的混杂因素无显著差异。TACE 单药治疗组和 TACE+RFA 治疗组的 DCR 分别为 33（69%）和 42（88%）（P<0.05），ORR 分别为 23（48%）和 35（73%）（P<0.05）。此外，TACE+RFA 组的 PFS 率明显高于 TACE 单药组（P<0.001）。
对于晚期 HCC 患者，TACE 联合 RFA 的治疗方案比 TACE 单药治疗具有更好的肿瘤反应率和生存率。
